These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 7653991

  • 1. In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin.
    Schultz RM, Merriman RL, Andis SL, Bonjouklian R, Grindey GB, Rutherford PG, Gallegos A, Massey K, Powis G.
    Anticancer Res; 1995; 15(4):1135-9. PubMed ID: 7653991
    [Abstract] [Full Text] [Related]

  • 2. Wortmannin, a phosphoinositide 3-kinase inhibitor, selectively enhances cytotoxicity of receptor-directed-toxin chimeras in vitro and in vivo.
    Davol PA, Bizuneh A, Frackelton AR.
    Anticancer Res; 1999; 19(3A):1705-13. PubMed ID: 10470104
    [Abstract] [Full Text] [Related]

  • 3. Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs.
    Norman BH, Shih C, Toth JE, Ray JE, Dodge JA, Johnson DW, Rutherford PG, Schultz RM, Worzalla JF, Vlahos CJ.
    J Med Chem; 1996 Mar 01; 39(5):1106-11. PubMed ID: 8676346
    [Abstract] [Full Text] [Related]

  • 4. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
    Ram TG, Ethier SP.
    Cell Growth Differ; 1996 May 01; 7(5):551-61. PubMed ID: 8732665
    [Abstract] [Full Text] [Related]

  • 5. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase.
    Powis G, Bonjouklian R, Berggren MM, Gallegos A, Abraham R, Ashendel C, Zalkow L, Matter WF, Dodge J, Grindey G.
    Cancer Res; 1994 May 01; 54(9):2419-23. PubMed ID: 8162590
    [Abstract] [Full Text] [Related]

  • 6. The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage.
    Price BD, Youmell MB.
    Cancer Res; 1996 Jan 15; 56(2):246-50. PubMed ID: 8542574
    [Abstract] [Full Text] [Related]

  • 7. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 8. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.
    Cancer Chemother Pharmacol; 2009 Jun 15; 64(1):53-65. PubMed ID: 18931998
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and in vitro evaluation of new wortmannin esters: potent inhibitors of phosphatidylinositol 3-kinase.
    Creemer LC, Kirst HA, Vlahos CJ, Schultz RM.
    J Med Chem; 1996 Dec 06; 39(25):5021-4. PubMed ID: 8960564
    [Abstract] [Full Text] [Related]

  • 10. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H, Genne P, Kadhim S, Bibeau L, Duchamp O, Ouellet F, deMuys JM, Bouffard DY, Attardo G.
    Cancer Chemother Pharmacol; 2002 Dec 06; 50(6):490-6. PubMed ID: 12451476
    [Abstract] [Full Text] [Related]

  • 11. Effects of wortmannin analogs on bone in vitro and in vivo.
    Sato M, Bryant HU, Dodge JA, Davis H, Matter WF, Vlahos CJ.
    J Pharmacol Exp Ther; 1996 Apr 06; 277(1):543-50. PubMed ID: 8613966
    [Abstract] [Full Text] [Related]

  • 12. Advances with phospholipid signalling as a target for anticancer drug development.
    Powis G, Berggren M, Gallegos A, Frew T, Hill S, Kozikowski A, Bonjouklian R, Zalkow L, Abraham R, Ashendel C.
    Acta Biochim Pol; 1995 Apr 06; 42(4):395-403. PubMed ID: 8852330
    [Abstract] [Full Text] [Related]

  • 13. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
    Varvaresou A, Iakovou K, Gikas E, Fichtner I, Fiebig HH, Kelland LR, Double JA, Bibby MC, Hendriks HR.
    Anticancer Res; 2004 Apr 06; 24(2B):907-19. PubMed ID: 15161044
    [Abstract] [Full Text] [Related]

  • 14. Effect of albumin on antitumor activity of diarylsulfonylureas.
    Schultz RM, Andis SL, Toth JE, Boder GB, Rinzel SM, Grindey GB.
    Anticancer Res; 1993 Apr 06; 13(6A):1939-43. PubMed ID: 8297099
    [Abstract] [Full Text] [Related]

  • 15. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
    Ram TG, Hosick HL, Ethier SP.
    J Cell Physiol; 2000 Jun 06; 183(3):301-13. PubMed ID: 10797304
    [Abstract] [Full Text] [Related]

  • 16. Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase.
    Lemke LE, Paine-Murrieta GD, Taylor CW, Powis G.
    Cancer Chemother Pharmacol; 1999 Jun 06; 44(6):491-7. PubMed ID: 10550570
    [Abstract] [Full Text] [Related]

  • 17. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
    Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466
    [Abstract] [Full Text] [Related]

  • 18. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
    Chou TC, Guan Y, Soenen DR, Danishefsky SJ, Boger DL.
    Cancer Chemother Pharmacol; 2005 Oct 15; 56(4):379-90. PubMed ID: 15875185
    [Abstract] [Full Text] [Related]

  • 19. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.
    Kadhim SA, Bowlin TL, Waud WR, Angers EG, Bibeau L, DeMuys JM, Bednarski K, Cimpoia A, Attardo G.
    Cancer Res; 1997 Nov 01; 57(21):4803-10. PubMed ID: 9354442
    [Abstract] [Full Text] [Related]

  • 20. Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3'-kinase inhibition in the KM20 human colon cancer cell line.
    Wang Q, Li N, Wang X, Kim MM, Evers BM.
    Clin Cancer Res; 2002 Jun 01; 8(6):1940-7. PubMed ID: 12060639
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.